Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-09-19
2006-09-19
Li, Q. Janice (Department: 1633)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000
Reexamination Certificate
active
07108982
ABSTRACT:
The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm.
REFERENCES:
patent: 6197770 (2001-03-01), Natchus et al.
patent: 2003/0149997 (2003-08-01), Hageman et al.
patent: WO 94/01123 (1994-01-01), None
patent: WO 95/17673 (1995-06-01), None
patent: WO 97/40849 (1997-11-01), None
patent: WO 01/02866 (2001-01-01), None
patent: WO 01/06262 (2001-01-01), None
G Chaine et al., Br F Ophthalmol, “Case-control study of the risk factors for age related macular degeneration,” 1998;82:996-1002.
JR Vingerling et al., American Journal of Epidemiology. “Age-related Macular Degeneration is Associated with Atherosclerosis,” 1995, vol. 142, No. 4, pp. 404-409.
Cobb et al, IOVS May 1997; 38:S354/1651.
Bizbiz et al, Atherosclerosis 1997; 131:73-8.
Nicoloff et al, Gen Pharmacol Aug. 2000;35:83-7.
Fulop et al, Clin Physiol Biochem 1990;8:273-82.
Kohner et al, Br Med Bull 1989;45:148-73.
Klein et al, Ophthalmol 2003;110:1273-80.
Grange JJ, et al., “Phthogenesis of abdominal aortic aneurysm: an update and look toward the future,” Cardiovasc Surg, 5(3):256-65, 1997.
Gregory, et al., “Features of autoimmunity in the abdominal aortic aneurysm,” Arc Surg, 131:85-88, 1996.
Guo, et al., “Matrix metalloproteinase and their inhibitors in vitreous in age-related macular degeneration and proliferative diabetic retinopathy” IOVS (Suppl) 38:S354, 1997.
He , et al., “The composition and mechanical properties of abdominal aortic aneurysm,” J Vasc Surg, 20(1): 6-13 1994.
Hirose, H. et al., “Molecular cloning of the complementary DNA for an additional member of the family of aortic aneurysm antigenic proteins,” J. Vasc. Surg. 26: 313-318, 1997.
Hirose, H., et al., “Genetic risk factor for abdominal aortic aneurysm: HLA-DR2(15), A Japanese study,” J. Vasc. Surg. 27:500-503, 1998.
Holmes DR, et al., “Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat,” J Surg Res, 63(1):305-9, 1996.
Holz, F., et al. “Analysis of lipid deposits extracted from human macular and peripheral bruch's membrane,” Arch. Ophthalmol., 112, 402-406, 1994.
Keen RR, et al., “Interleukin-1 beta induces differential gene expression in aortic smooth muscle,” J Vasc Surg, 20(5):774-86, 1994.
Koch, et al., Human abdominal aortic aneurysms, Am. J. Path., 137:1199-1213, 1990.
Kuivaniemi, et al., “Fibulin-2 exhibits high degree of variability, but no structural changes concordant with abdominal aortic aneurysm,” Eur. J. Hum. Gen 6:642-646, 1998.
Kuivaniemi, H. et al., “Genetic causes of aortic aneurysms,” J. Clin. Invest. 88:1441-1444, 1991.
Menashi, S., “Collagen in abdominal aortic aneurysm: typing, content, and degradation,” J. Vasc. Surg., 578-582, 1987.
Minion DJ, et al., “Elastin is increased in abdominal aortic aneurysms,” J Surg Res, 57(4):443-6, 1994.
Miralles M, et al., “Indomethacin inhibits expansion of experimental aortic aneurysms via inhibiting the cox2 isoform of cyclooxygenase,” J Vasc Surg, 29(5):884-93, 1999.
Moore G, et al., “Suppression of experimental abdominal aortic aneurysms by systemic treatment with hydroxamate-based matrix metalloproteinase inhibitor (RS 132908),” J Vasc Surg, 20(3):522-32, 1999.
Newman KM, et al., “Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources,” Connect Tissue Res, 30(4):265-76, 1994.
Newsome, D., et al., “Reaction of specific extracellular matrix molecules in drusens, bruch's membrane, and ciliary body,”Amer. J. Ophthalmol., 104,373-381, 1987.
Ozsvath, K., et al., “Molecular mimicry in human aortic aneruysmal diseases,” Annals NY Acad. Sci., 800:288-293, 1996.
Powell JT, et al., “Interaction between fibrillin genotype and blood pressure and the develop aneurysmal disease,” Ann NY Acad Sci, 800(-HD-):198-207, 1996.
Rasmussen TE, et al., “Genetic risk factors in inflammatory abdominal aneurysms: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element,” J Vasc Surg, 25(2):356-64, 1997.
Reilly, J. M., “Plasminogen activators in abdominal aortic aneurysmal disease,” Annals NY Acad. Sci., 800:151-156, 1996.
Robert L, et al., “Elastin-elastase-atherosclerosis revisited,” Atherosclerosis, 140(2):281-95, 1998.
Sacks, S.G. et al., “The pathogenesis of optic nerve drusen. A hypothesis,” Archives of Ophthalmology 95(3), pp. 425-8, 1977.
Sakalihasan N, et al., “Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms,” J Vasc Surg, 24(1):127-33, 1996.
Sauvage M, et al., “Localization of elastin mRNA and TGF-beta in rat aorta and caudal artery as a function of age,” Cell Tissue Res. 29:305-314, 1998.
Sobolewaski, K. et al., Act. Biocim. Polonica, 42:301-308, 1995.
Stanley JC et al., “Splanchnic and renal artery aneurysms,” pp. 468-481 in WS Moore,Vascular Surgery: A Comprehensive Review, WB Saunders, 1998.
Starita, C., et al., Exp. Eye Res., 62, 565-572, 1996.
Allaire E, et al., “Local overexpression of TIMP-1 prevents aortic aneurysm degeneration an a rat model,” J Clin Invest, 102(7), 1413-20, 1998.
Anidjar S, et al., “Experimental study of determinants of aneurysmal expansion of the abdomen,” Ann Vasc Surg, 9(2), 127-36, 1994.
Aoyagi M, et al., “Smooth muscle cell proliferation, elastin formation, and tropoelastin transcripts during the development of intimal thickening in rabbit carotid arteries after endothelial denudation,” Histochem Cell Biol 107:117, 1997.
Beckman, EN, “Plasma cell infiltrates in atherrosclerotic abdominal aortic aneurysms,” AM. J. Clin. Pathol., 85:21-24, 1986.
Bigatel DA, et al., “The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms,” J Vasc Surg, 29(1):130-8; discussion 138-9, 1999.
Bilato and Crow “Atherosclerosis and the vascular biology of aging.” Aging 8(4):221-34, 1996.
Bobryshev, Y. V. et al., “Immunophenotypic analysis of the aortic aneursm wall suggests that vascular dendritic cells are involved in immune reponses,” Cardiovascular Surgery, 6(3):240-249, 1998.
Boyle JR, et al., “Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease,” Eur J Vasc Endovasc Surg, 16(5):408-14, 1998.
Boyle JR, et al., “Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease,” J Vasc Surg, 27(2):354-61, 1998.
Brophy, CM et al., “The role of inflammmation in nonspecific abdomonal aortic aneurysm disease,” Annals Vasc. Surg., 5:229-233, 1991.
Brophy, CM et al., “Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: a preliminary report,” J Surg Research 50:653-657, 1991.
Buckmaster MJ, et al., “Source of elastin-degrading enzymes in mycotic aortic aneurysms: bacterial or inflammatory response?,” Cardiovasc Surg, 71:16-26, 1999.
Campa, “Elastin degradation in abdominal aortic aneurysms,” JS, Athersclerosis 65:13-21, 1987.
Capella, et al. “Complement activation and subclassification of tissue immunoglobin G in the abdominal aortic aneurysm,” (J.
Li Q. Janice
Townsend and Townsend / and Crew LLP
University of Iowa Research Foundation
LandOfFree
Diagnostics and the therapeutics for macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostics and the therapeutics for macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and the therapeutics for macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3604928